U.S. Markets open in 2 hrs 54 mins
  • S&P Futures

    4,225.25
    +15.50 (+0.37%)
     
  • Dow Futures

    33,408.00
    +104.00 (+0.31%)
     
  • Nasdaq Futures

    13,372.50
    +61.25 (+0.46%)
     
  • Russell 2000 Futures

    1,985.10
    +8.80 (+0.45%)
     
  • Crude Oil

    94.19
    -0.15 (-0.16%)
     
  • Gold

    1,803.00
    -4.20 (-0.23%)
     
  • Silver

    20.25
    -0.10 (-0.51%)
     
  • EUR/USD

    1.0293
    -0.0032 (-0.3088%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.16
    +0.42 (+2.13%)
     
  • GBP/USD

    1.2122
    -0.0080 (-0.6582%)
     
  • USD/JPY

    133.5260
    +0.5270 (+0.3962%)
     
  • BTC-USD

    23,882.48
    -583.82 (-2.39%)
     
  • CMC Crypto 200

    567.83
    -6.92 (-1.20%)
     
  • FTSE 100

    7,489.26
    +23.35 (+0.31%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Bionano Genomics to Present at the 2022 H.C. Wainwright Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Bionano Genomics
Bionano Genomics

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present a company overview available for on-demand listening starting Tuesday, May 24, 2022, at 7:00 a.m. Eastern Time. Interested parties can register for the conference and view the presentation here: www.hcwevents.com/globalconference.

About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com